Aquestive Therapeutics (NASDAQ:AQST) Given a $31.00 Price Target at Wedbush

Aquestive Therapeutics (NASDAQ:AQST) has been assigned a $31.00 target price by investment analysts at Wedbush in a research report issued to clients and investors on Wednesday, May 8th, TipRanks reports. The brokerage presently has a “buy” rating on the stock.

Several other equities analysts also recently issued reports on AQST. Zacks Investment Research raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 10th. Lake Street Capital reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Wednesday, February 20th. BMO Capital Markets dropped their target price on shares of Aquestive Therapeutics from $24.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, March 15th. Finally, HC Wainwright initiated coverage on shares of Aquestive Therapeutics in a research note on Monday, April 22nd. They issued a “buy” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $19.54.

Shares of Aquestive Therapeutics stock opened at $3.72 on Wednesday. Aquestive Therapeutics has a twelve month low of $3.65 and a twelve month high of $20.70. The stock has a market cap of $98.67 million and a PE ratio of -1.33. The company has a current ratio of 1.89, a quick ratio of 1.71 and a debt-to-equity ratio of 4.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). The company had revenue of $12.64 million for the quarter, compared to analysts’ expectations of $10.66 million. Research analysts forecast that Aquestive Therapeutics will post -2.31 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citigroup Inc. raised its stake in shares of Aquestive Therapeutics by 317.6% during the first quarter. Citigroup Inc. now owns 3,662 shares of the company’s stock worth $25,000 after buying an additional 2,785 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth approximately $28,000. American International Group Inc. raised its stake in shares of Aquestive Therapeutics by 109.7% during the first quarter. American International Group Inc. now owns 7,211 shares of the company’s stock worth $50,000 after buying an additional 3,772 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Aquestive Therapeutics during the first quarter worth approximately $65,000. Finally, Spark Investment Management LLC bought a new stake in shares of Aquestive Therapeutics during the first quarter worth approximately $80,000. 57.75% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Featured Story: What is the Gross Domestic Product (GDP)?

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.